The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States

References

• World Health Organization (WHO). Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). Interim statement on the composition of current COVID-19 vaccines. 2022. https://www.who.int/news/item/17-06-2022-interim-statement-on–the-composition-of-current-COVID-19-vaccines
   Google Scholar
• COVID-19 Weekly Epidemiological Update. Edition 95. 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Centers for Disease Control and Prevention. Variant proportions 2022. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
   Google Scholar
• Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121–4123. PubMed PMID: 29790939; PubMed Central PMCID: PMCPMC6247931.
   PubMed Web of Science ®Google Scholar
• MODERNA. Moderna announces clinical update on bivalent COVID-19 booster platform 2022. https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Clinical-Update-on-Bivalent-COVID-19-Booster-Platform/default.aspx
   Google Scholar
• MODERNA. New Release: Moderna announces Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrates superior antibody response against omicron. 2022. https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx
   Google Scholar
• Hoge S. mRNA-1273.214 Moderna COVID-19 Invetigational bivalent vaccine C(original + Omicron). Presentation to the Vaccines and Related Biological Products Advisory Committee. 2022. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement
   Google Scholar
• European Medicines Agency. EMA regular press briefing on COVID-19. 2022. https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-19
   Google Scholar
• FDA U.S. Food & Drug Administration. Vaccines and related biological products advisory committee June 28, 2022 Meeting Announcement. 2022. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement
   Google Scholar
• Shiri T, Evans M, Talarico CA, et al. Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: a Population-Based modeling study using the UK as an example. Vaccines. 2021;9(10):1180.
   Web of Science ®Google Scholar
• Institute for Health Metrics Evaluation (IHME). COVID-19 Projections. United States of America. Used with permission. 2022. https://covid19.healthdata.org/united-states-of-america
   Google Scholar
• Lessler J. COVID-19 Scenario Modeling Hub. Round 13: Planning scenarios projecting COVID-19 burden March 2022-March 2023 under current vaccination policy. Presentation to the Vaccines and Related Biological Products Advisory Committee meeting. 2022. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement
   Google Scholar
• Centers for Disease Control and Prevention. Interim updated planning guidance on allocating and targeting pandemic influenza vaccine during an influenza pandemic. 2018. https://www.cdc.gov/flu/pandemic-resources/pdf/2018-Influenza-Guidance.pdf
   Google Scholar
• Institute for Health Metrics and Evaluation (IHME). COVID-19 model update: Omicron and waning immunity. 2021. www.healthdata.org
   Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the omicron (B.1.1.529) variant of concern. medRxiv. 2021.
   Google Scholar
• Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of covid-19 vaccines against SARS-CoV-2 omicron variant (B.1.1.529): a systematic review with Meta-analysis and Meta-regression. medRxiv. 2022.
   Google Scholar
• UK Health Security Agency. COVID-19 vaccine surveillance report. Week 24. 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1083443/Vaccine-surveillance-report-week-24.pdf
   Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Hogan AB, Wu SL, Dooha P. Imperial College COVID-19 response team. Report 48: the value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant. 2021. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-48-global-omicron/
   Google Scholar
• Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2208343
   Web of Science ®Google Scholar
• Khoury DS, Steain M, Triccas JA, et al. A Meta-analysis of early results to predict vaccine efficacy against omicron. medRxiv. 2021.
   PubMedGoogle Scholar
• Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against covid-19. medRxiv. 2022.
   PubMedGoogle Scholar
• Pilz S, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. COVID data tracker. 2022. https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic
   Google Scholar
• Reese H, Iuliano AD, Patel NN, et al. Estimated incidence of coronavirus disease 2019 (COVID-19) illness and Hospitalization-United States, February-September 2020. Clin Infect Dis. 2021;72(12):e1010–e1017.
   PubMed Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and Meta-analysis. JAMA Netw Open. 2021;4(12):e2137257.
   PubMed Web of Science ®Google Scholar
• Wang L, Berger NA, Kaelber DC, et al. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after omicron emerged in the US. medRxiv. 2022.
   Google Scholar
• Qasmieh SA, Robertson MM, Teasdale CA, et al. The prevalence of SARS-CoV-2 infection and uptake of COVID-19 antiviral treatments during the BA.2/BA.2.12.1 surge, New York city, April-May 2022. medRxiv. 2022.
   Google Scholar
• Chalkias D, Eder F, Khetan S, et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine. 2022. https://www.researchsquare.com/article/rs-1555201/v1
   Google Scholar
• Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6.
   PubMedGoogle Scholar
• Head E, van Elsland S. Omicron largely evades immunity from past infection or two vaccine doses [updated 17 December 2021; cited 2022 June 30]. https://www.imperial.ac.uk/news/232698/omicron-largely-evades-immunity-from-past/
   Google Scholar